We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+56.37%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
+$17M
Cap. Flow
-$11.6M
Cap. Flow %
-11.47%
Top 10 Hldgs %
53.57%
Holding
52
New
16
Increased
7
Reduced
8
Closed
17

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$5.53M
2
SMMT icon
Summit Therapeutics
SMMT
+$4.78M
3
CDTX
Cidara Therapeutics
CDTX
+$4.37M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.62M
5
IQV icon
IQVIA
IQV
+$3.48M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$7.13M
2
VRNA
Verona Pharma
VRNA
+$6.52M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.1M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.74M
5
TVTX icon
Travere Therapeutics
TVTX
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYTX icon
51
Kyverna Therapeutics
KYTX
$452M
– –
-142,542
Closed -$438K
LSB
52
DELISTED
LakeShore Biopharma
LSB
– –
-30,792
Closed -$31.4K
1 2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Superstring Capital Management held 52 positions worth $102M, up 20% from $84.5M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Superstring Capital Management withdrew a net $11.6M in Q3 2025, closing 17 positions and reducing 8 holdings. Its most notable exit was Verona Pharma, an estimated $6.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Immunovant worth $5.5M.

  • Superstring Capital Management's largest Q3 2025 buy was Immunovant: 341,348 shares worth $5.5M.
  • Superstring Capital Management added most to Zai Lab in Q3 2025, an estimated $2.26M increase.
  • Superstring Capital Management's biggest Q3 2025 reduction was Cogent Biosciences, cutting an estimated $7.13M.
  • Superstring Capital Management fully exited Verona Pharma in Q3 2025, selling an estimated $6.52M.
  • Superstring Capital Management's ten largest holdings make up 54% of its $102M portfolio in Q3 2025.
  • Superstring Capital Management opened 16 new positions and closed 17 in Q3 2025.
  • Superstring Capital Management's portfolio value rose 20% quarter-over-quarter to $102M.

Based on Superstring Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.